Table 1 The basic information for all subjects
Variable | Treated (N = 51) | Untreated (N = 12) | Controls (N = 33) |
|---|---|---|---|
Gender(F/M) | 39/12 | 10/2 | 27/6 |
Age(y) | 36.8 ± 11.7 | 42.7 ± 8.9 | 30.2 ± 5.6* |
BMI (kg/m2) | 24.26 ± 4.36 | 23.53 ± 3.27 | 21.12 ± 1.77* |
PRL (ng/ml) | 17.6 (1.6, 417.0) | 43.1 (14.4, 151.1) * | — |
Micro/Macro | 39/12 | 11/1 | — |
D-max(mm) | 6.5 ± 3.6 | 6.1 ± 2.5 | — |
Treatment | |||
Bromocriptine (N) | 45 | — | — |
Duration (m) | 26 (3, 98) | — | — |
Total dose(mg) | 3412.5 (112.5, 39,067.5) | — | — |
Max-dose(mg/d) | 5.0 (1.3, 22.0) | — | — |
Cabergoline (N) | 6 | — | — |
Duration (m) | 13 (3,59) | — | — |
Total dose(mg) | 179.7 (20.0, 560.0) | — | — |
Max-dose(mg/w) | 2.5 (1.3,4.0) | — | — |